Corbus Pharmaceuticals initiates MAD portion of its Phase 1 trial for CRB-913

Corbus Pharmaceuticals (CRBP) announced the initiation of the multiple ascending dose, MAD, portion of its Phase 1 trial for CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. This follows safety and pharmacokinetics data analysis of the single ascending dose, SAD, study launched in March. The MAD portion of this clinical study is scheduled for completion in the third quarter of this year. The MAD portion of the Phase 1 trial is designed to test a once-daily dosing of CRB-913 for 7 days. Similarly to the SAD study, the MAD study is undertaken with healthy volunteers and focuses on safety, tolerability and PK of increasing doses of CRB-913. The study is being conducted in the United States.